Clinical Trials Logo

TOF clinical trials

View clinical trials related to TOF.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05976204 Completed - Clinical trials for Congenital Heart Disease

Prognostic Value of NLR, TLR, and ALC in Predicting ToF Primary Repair Outcome

Start date: January 1, 2020
Phase:
Study type: Observational

Tetralogy of Fallot (ToF) were cyanotic congenital heart disease with chronic hypoxia which increases the risk of exacerbated inflammatory response in ToF primary repair. Various studies have recently shown inflammatory biomarkers to predict morbidity and mortality in hypoxemic patients, but they are not readily available and expensive.This study aims to compare the prognostic value of neutrophil-lymphocyte ratio (NLR), absolute lymphocyte count (ALC), and thrombocyte-lymphocyte ratio (TLR) in predicting ToF primary repair outcomes. This was a retrospective observational study on ToF primary repair in National Cardiovascular Center Harapan Kita between Januari 2020 until December 2022. Preoperative NLR, ALC, and TLR were derived from blood test obtained <14 days before surgery. The primary endpoints were redo surgery, 30-day mortality, and complications. The secondary endpoints were hospital length of stay (HLOS) and postoperative LOS.

NCT ID: NCT04762420 Completed - Anesthesia Clinical Trials

Sugammadex Dosing: Anaesthesiologist Clinical Perception Versus Quantitative Monitoring

Start date: February 1, 2019
Phase:
Study type: Observational

Many clinicians continue to rely on subjective evaluation in making decisions about the adequacy of neuromuscular function before tracheal extubation rather than using quantitative monitoring. The aim was to compare the sugammadex dose as suggested by senior anaesthesiologists (SSD) based on clinical experience versus the dose determined by quantitative monitoring (QSD) to determine if the subjective dose was appropriate.